|
Italian wheelchair basketball team, sponsored by Menarini, was presented to the press and public in Italy. The challenges they will be facing in the Italian Serie A and Eurocup 3 are already on the horizon
FLORENCE, Italy, Nov. 24, 2025 /PRNewswire/ -- Ten international talents, differing in both age and experience but united by the desire to make a difference, both in Italy and Europe. After the opening match of the 2025/2026 season, the new roster of the Volpi Rosse Menarini wheelchair basketball team was officially presented today, ready to start competing in the FIPIC Serie A championship and the Eurocup 3.
This year, both home and away, the coaches will be leading a team of players with very different backgrounds. From Spain to Finland, from Sweden to France, via Italy and Brazil, the Volpi Rosse Menarini team can count on a truly international team of players. A team which is now facing the matches of the Italian championship, a necessary testing ground for the Eurocup 3, scheduled from 12th to 15th March 2026 in Amsterdam.
Founded in 2005, the Volpi Rosse Menarini team has become a symbol of how personal growth can be achieved through sport: the passion, talent, and determination of these athletes have made every match a tangible example of inclusion. By their side is the Menarini Pharmaceutical Group which has been supporting the team as title sponsor since 2011 and shares the fundamental values of solidarity and sporting ethics.
"It is as if we are two communicating vessels, the Volpi Rosse Menarini and our Group share, every day, the same values that we believe in", commented Lucia and Alberto Giovanni Aleotti, shareholders and members of the Menarini Board. "What has always distinguished the team is their tenacity, necessary to keep on improving and look to the future with confidence and commitment. Go for it Volpi Rosse Menarini!".
But the story of the Volpi Rosse Menarini does not end here as they also dedicate time to promoting inclusion and awareness projects amongst students in schools in Florence, Italy.
The support of the Menarini Group goes beyond Italy too as they also support a Spanish wheelchair basketball team, the Menarini Joventut, from Badalona (Barcelona) fostering, day after day, a greater sense of awareness with the aim of creating a more attentive and inclusive community.
The Volpi Rosse Menarini team was established in 2005 as an association for the promotion of social initiatives and later went on to become an ASD in 2011, the same year in which the Menarini Group began sponsoring the team. From a sporting perspective, the team has achieved significant results in wheelchair basketball. After finishing third in the Italian Under 22 Championship, and becoming UISP Italian Champion in the 2017/18 season, the team continued to flourish, finishing second in the Italian Under 22 Championship and winning the Kavala International Tournament in Greece the following season. After the pandemic-induced hiatus, in the 2020/21 season, they triumphed in the Italian Under 22 and the Serie B Championships, earning the promotion to the top division. In the following seasons, they consolidated their presence in Serie A, finishing eighth in the 2021/22 season, while in 2022/23 they finished sixth in the league and triumphed in the Eurocup 3 Tournament in France. In 2023/24, they finished fifth in Serie A and second in the Eurocup 3 in Spain whilst in the last season (2024/25) they finished fifth in Serie A, confirming their consistently competitive status.
The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with €4,603 million in consolidated turnover and more than 17,000 employees. With 9 centres for Research & Development, Menarini's products are present in the most important treatment areas, including those of cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesic products. Pharmaceutical production is carried out in the Group's 18 manufacturing plants, located in Italy and abroad, which produce over 609 million packets of product a year and distribute them to five continents. Menarini's pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients throughout the world. www.menarini.com
Italian wheelchair basketball team, sponsored by Menarini, was presented to the press and public in Italy. The challenges they will be facing in the Italian Serie A and Eurocup 3 are already on the horizon
FLORENCE, Italy, Nov. 24, 2025 /PRNewswire/ -- Ten international talents, differing in both age and experience but united by the desire to make a difference, both in Italy and Europe. After the opening match of the 2025/2026 season, the new roster of the Volpi Rosse Menarini wheelchair basketball team was officially presented today, ready to start competing in the FIPIC Serie A championship and the Eurocup 3.
This year, both home and away, the coaches will be leading a team of players with very different backgrounds. From Spain to Finland, from Sweden to France, via Italy and Brazil, the Volpi Rosse Menarini team can count on a truly international team of players. A team which is now facing the matches of the Italian championship, a necessary testing ground for the Eurocup 3, scheduled from 12th to 15th March 2026 in Amsterdam.
Founded in 2005, the Volpi Rosse Menarini team has become a symbol of how personal growth can be achieved through sport: the passion, talent, and determination of these athletes have made every match a tangible example of inclusion. By their side is the Menarini Pharmaceutical Group which has been supporting the team as title sponsor since 2011 and shares the fundamental values of solidarity and sporting ethics.
"It is as if we are two communicating vessels, the Volpi Rosse Menarini and our Group share, every day, the same values that we believe in", commented Lucia and Alberto Giovanni Aleotti, shareholders and members of the Menarini Board. "What has always distinguished the team is their tenacity, necessary to keep on improving and look to the future with confidence and commitment. Go for it Volpi Rosse Menarini!".
But the story of the Volpi Rosse Menarini does not end here as they also dedicate time to promoting inclusion and awareness projects amongst students in schools in Florence, Italy.
The support of the Menarini Group goes beyond Italy too as they also support a Spanish wheelchair basketball team, the Menarini Joventut, from Badalona (Barcelona) fostering, day after day, a greater sense of awareness with the aim of creating a more attentive and inclusive community.
The Volpi Rosse Menarini team was established in 2005 as an association for the promotion of social initiatives and later went on to become an ASD in 2011, the same year in which the Menarini Group began sponsoring the team. From a sporting perspective, the team has achieved significant results in wheelchair basketball. After finishing third in the Italian Under 22 Championship, and becoming UISP Italian Champion in the 2017/18 season, the team continued to flourish, finishing second in the Italian Under 22 Championship and winning the Kavala International Tournament in Greece the following season. After the pandemic-induced hiatus, in the 2020/21 season, they triumphed in the Italian Under 22 and the Serie B Championships, earning the promotion to the top division. In the following seasons, they consolidated their presence in Serie A, finishing eighth in the 2021/22 season, while in 2022/23 they finished sixth in the league and triumphed in the Eurocup 3 Tournament in France. In 2023/24, they finished fifth in Serie A and second in the Eurocup 3 in Spain whilst in the last season (2024/25) they finished fifth in Serie A, confirming their consistently competitive status.
The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with €4,603 million in consolidated turnover and more than 17,000 employees. With 9 centres for Research & Development, Menarini's products are present in the most important treatment areas, including those of cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesic products. Pharmaceutical production is carried out in the Group's 18 manufacturing plants, located in Italy and abroad, which produce over 609 million packets of product a year and distribute them to five continents. Menarini's pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients throughout the world. www.menarini.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
The Volpi Rosse Menarini: The 'Fantastic Ten' are ready for the 2025 - 2026 Season
The Volpi Rosse Menarini: The 'Fantastic Ten' are ready for the 2025 - 2026 Season
SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. The evening, co-hosted by Founding Platinum Sponsor Wilson Sonsini and the BayHelix Group, recognized outstanding achievements in healthcare investment, financing, and deal-making over the past year.
This year's awards honored the companies and individuals at the forefront of China's dynamic healthcare sector — from landmark licensing and partnership agreements to capital markets milestones and private financings that are reshaping the industry. Award recipients were selected through a formal vote conducted by CHIC's Founders and 2026 Organizing Committee & Working Group, whose collective expertise spans venture capital, private equity, and global healthcare leadership.
Award Winners
IPO of the Year
Winner: Insilico Medicine
Accepted by: Leah Liu, VP and Global Head of IR & Capital Markets, Insilico Medicine
Presenter: Richard Wang, China Partner, Wilson Sonsini
Private Financing of the Year — Tied
Co-Winner: Kailera Therapeutics
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui (Kailera Therapeutics was built on Hengrui assets)
Presenter: Kan Chen, Co-Head of Healthcare, Qiming Venture Partners
Co-Winner: Vor Bio
Accepted by: Jianmin Fang, CEO, RemeGen (Vor Bio's leading project is from RemeGen)
Presenter: Cyber Cao, Managing Director, HSG
Deal of the Year — Tied
Co-Winner: Hengrui Pharma – GSK
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui; and Ming Fang, PhD, Senior Director, Search & Evaluation, Business Development, GSK
Presenter: Steve Yang, Co-Founder, the BayHelix Group; Co-CEO, WuXi Apptec
Co-Winner: Innovent – Takeda
Accepted by: Sophy Wang, Board Secretary & Global BD, Innovent; and Eric Yeung, Head of Oncology and Global Business Development, Takeda
Presenter: Kevin Yuan, CEO, Hankang Capital
About CHIC 2026
The China Healthcare Investment Conference (CHIC) is a premier platform connecting innovation and investment in China's healthcare sector. Now in its 12th year, CHIC brings together senior decision-makers including venture capital and private equity investors, pharmaceutical executives, and biotech and medtech CEOs. The 2026 conference was held on March 23–24 at The Ritz-Carlton Hotel Pudong, Shanghai, under the theme "Innovation in Healthcare – The Answer to Uncertainty."
About the Gala Dinner Co-Hosts
Wilson Sonsini is a leading legal advisor to life sciences, and biotechnology industries, offering integrated counsel across the full spectrum of a company's life cycle — from early-stage intellectual property strategy and patent prosecution to complex technology transactions, licensing, collaborations, as well as M&As, IPOs and capital market offerings. As Founding Platinum Sponsor of CHIC, Wilson Sonsini has been a steadfast partner in the conference's mission to connect healthcare innovation with global capital.
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix serves as a co-host of the CHIC Gala Dinner and is a longstanding partner in advancing the global development of China's healthcare sector.
CHIC 2026 Founding Individuals & Organizing Committee / Working Group
The following individuals served as the voting body for the CHIC 2026 Awards, representing the CHIC Founding Individuals and the Organizing Committee & Working Group.
Founders
Marietta Wu, Managing Director, Quan Capital
Frank Kung, Managing Partner, Vivo Capital
Hongbo Lu, Managing Member, NEXTBio Capital
James Li, Venture Partner, Frazier Lifesciences
Norman Chen, CEO, The Asian American Foundation
2026 Organizing Committee & Working Group
Cyber Cao, Managing Director, HSG
Jialing Dai, President & Publisher, PharmaDJ
Tess Cameron, Managing Director, RA Capital Management
Kan Chen, Co-Head of Healthcare, Qiming Venture Partners
Sean Zhang, Executive Director, Vivo Capital
Dandan Dong, Venture Partner, TCGX
Anna Chen, Partner, Frazier Life Sciences
Yuan Yuan, Head of Platform Development, China, NEXTBio Capita
Zhanghang Yan, Vice President, Quan Capital
Yun Gao, Principal, Lilly Asia Ventures
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
